
PREVENTION DOESN'T GROW ON TREES

THE REAL COST OF PREP



Sean Kelly, MD
Vanderbilt Division of Infectious Diseases

Objectives

- Understand the drug cost structure
- Review the different Truvada® cost assistance programs
- Review cost effectiveness studies of pre-exposure prophylaxis
- Discuss different patient scenarios



The Cost of Truvada®

Out-of-pocket cost of TDF/FTC*

• Per pill: \$67.03

• Per month: \$1,876.84

• Per year: \$24,465.95



*Average Wholesale Price

The Cost of Truvada®


- Cheaper by component?
 - Tenofovir disoproxil fumarate: \$40.53/day*
 - Emtricitabine: \$21.26/day*
- \$61.79/day
- \$1,730/month
- \$22,553.35/year

Why so high?

Research and development (such as DISCOVER trial)



The Different Costs



Manufacturer to wholesaler

- Wholesale Acquisition Cost (WAC)
 - Estimate of manufacturer's list price for a drug to wholesalers/direct drug purchasers, as defined by federal law
 - Does not include discounts or rebates
- Average Manufacturer Price (AMP)
 - Price a manufacturer charges purchasers, after discounts are taken into account, as defined by federal law
- Average Sales Price (ASP)
 - Cost from manufacturer to purchaser, inclusive of all discounts/rebates
 - Limited only to Medicare Part B-covered drugs

Wholesaler to pharmacy

- Average Wholesale Price (AWP)
 - Estimated price paid by pharmacies to purchase drug products from wholesalers
 - This is the "list price," though not a true representation of actual market prices
 - Discounts/rebates not considered in this figure
- Estimated Acquisition Cost (EAC)
 - Estimated price state Medicaid programs use to reimburse pharmacies for the cost of the drug plus a dispensing fee
- Average Actual Cost (AAC)
 - Final cost paid by pharmacies to their wholesalers after all discounts have been deducted
 - Derived from audits of pharmacy invoices

Pharmacy to patient

- Usual and Customary Price (U&CP)
 - Cost to consumer from a retail pharmacy
 - Without the use of insurance



The Third Party

- Private, employer and federal insurance plans negotiate and contract for drug costs
- Insurance premiums (or other contributions) pay into this service
- The third party pays the pharmacy a portion
- The patient's makes up the remainder of the drug cost with the copayment



Truvada® Coverage


- Virtually all insurance plans cover TDF/FTC for the indication of HIV prevention
 - Variable copays
 - Prior authorization may be required
 - Though as low as 2% now require PAs
- Medicare/Medicaid cover TDF/FTC
- Flexible Spending Accounts (FSAs) can cover up to \$2,600 of out-of-pocket costs



Prior Authorization

NAVITUS	Drug Prior Authorization tricitabine/tenofovir (TRUVADA)	
STEP 1: CLEARLY PRINT AND COMPLETE TO	EXPEDITE PROCESSING	
Date: 02/28/2017	Prescriber First Sean Kelly	
Patient First & Last Name:	Prescriber NPI: 1932477171	
Palient Address:	Prescriber Address: 1211 21st Ave S Suite 102A Nashville TN 37232	
Patient ID:	Prescriber Phone: 615-936-1174	
Patient Date of Birth:	Prescriber Fax; 615-875-0666	
DIAGNOSIS A: Coverage for Human Immunodeficiency Virus (HIV) or Hepatitis B Virus (HBV) Infected patients (Approve for Lifetime) Prescribed for the active treatment of HIV or HBV DIAGNOSIS B: Post-Exposure Prophylaxis (Approve for 1 Month) Prescribed for post-exposure prophylaxis following suspected or confirmed Human Immunodeficiency Virus (HIV) exposure DIAGNOSIS C: Pre-Exposure Prophylaxis (Initial Coverage) (Approve for 3 Months) Patient is at high risk for contracting Human Immunodeficiency Virus (HIV) due to sexual transmission and receiving TRUVADA for pre-exposure prophylaxis. If not due to sexual transmission, please explain other reason patient is at high risk for contracting HIV:		
AND ☐ Patient is ≥ 18 years of age AND ☐ Patient is HIV negative: Please provide date of last test: AND ☐ Prescriber has completed the REMS Prescriber Checkfist: http://www.inuvadapreprems.com/Content/pdf/Checkfist for Prescribers.pdf AND ☐ Patient and prescriber have signed the REMS Agreement Form and it is saved in the patient's medical chart; http://www.truvadapreprems.com/Content/pdf/Agreement Form.pdf Please provide expected duration of treatment:		
DIAGNOSIS D: Pre-Exposure Prophylaxis (Cont ☑ Patient is Human Immunodeficiency Virus Please provide date of last test: 1293/2016	(HIV) negative	
STEP 3: SIGN AND FAX TO: NAVITUS PRIOR AU Prescriber Signature:	Date: 2-23-17	
If patient meets criteria, allow 2 business days for p		

Financial Assistance



Conav Assistance





Gilead Advancing Access Co-pay Card

gileadcopay.com 877-505-6986

- \$7,200 max/calendar year
- No income restrictions
- Covers co-pays, deductibles and co-insurance
- Re-apply annually as needed
- US resident
- Not available for persons with Medicaid, Medicare, VA or other state/federal prescription drug programs


If pharmacy is unable to process Gilead's Co-pay Card, keep sales and pharmacy receipts. Call number on back of co-pay card. Submit paperwork for reimbursement for all refills. Some restrictions apply: terms, conditions at *gileadcopay.com*.






Gilead Advancing Access Program

- \$7,200/calendar year benefit
 - Increased from \$3,600 to \$4,200 in January 2018
 - Increased from \$4,200 to \$7,200 in September 2018
- No income limitation
- Federal beneficiaries excluded
- Usually goes toward deductible
 - Beware of copay accumulator programs
 - Manufacturer copay assistance will no longer count toward deductible











Medication Access Program



Medication Assistance Program



Medication Assistance Program

ADVANCING	ENROLLMENT FORM PAGE 1 OF 3	
ACCESS°	PHOME: 1.800.228.2058 EAV: 1.800.218.6857	
1. REQUESTED PATIENT SUPPORT (REQUIRED)	ADVANCING ACCESS ENROLLMENT FORM PHONE: 1-800-226-2056	FAX:1-800-216-6857
Benefits Investigation Prior Authorization and	PATIENT NAME:	DA
Patient Assistance Program (PAP) or Medication Assistance Program (MAP) El		ADVANCING ACCESS ENROLLMENT FORM PHONE: 1800-226-2056 FAX: 1800-216-6857 PAGE 3 OF 3
2. GILEAD MEDICATION PRESCRIBED (REQUIRED)	8. PATIENT AUTHORIZATION FOR USE AND DISCLOSURE OF PERSONAL HEALTH	PATIENT NAME: DATE OF BIRTH:
Product Name:	I understand that I must complete this enrollment form before I of	
If requesting TRUVADA, please indicate for: Treatment PrEP/Pr	Advancing Access ("Program") and the Patient Assistance Program	am/Medication Assi
	of this process, Gilead and its agents and contractors (collectively,	
3. PATIENT INFORMATION (REQUIRED)	my personal and medical information as described below. I herel disclose my personal and medical information as described below	by authorize my ne
First Name: Last Name:	PAP/MAP, all in accordance with this authorization, and I authorize	
Address: Apt/Unit #	with the authorization.	
State: Zip Code:	Information to Be Disclosed: Personal health information ("PHI"),	
Email:	name, mailing address, financial information, and insurance info	
Alternate Contact Name:	(including information about my HIV-related status or treatment condition), and all information provided on this enrollment form.	
CONTACT AUTHORIZATION	Persons Authorized to Disclose My Information: My healthcare pr	
I authorize Advancing Access to leave a detailed message, including the name of m	medication, and any health plans or programs that provide me h	noviders, including
4. INSURANCE INFORMATION (REQUIRED) PLEAS	providers may receive remuneration for disclosing my PHI pursua	uant to this authoriz
Patient is insured (Please fill out all of the applicable insurance information	Persons to Which My Information May Be Disclosed: Gilead, inclu	
below. Attach copy – front and back – of patient card.) Primary Insurance:	administration of the Program and the PAP/MAP.	Has the patient applied for an insurance plan offered through a state insurance marketologic (also known as an exchange)? Wes No If Yes, date of application:
Plan name:	Purposes for Which the Disclosures Are to Be Made: Disclosures of	
Subscriber Policy Holder	disclose the PHI for purposes of: 1) completing the enrollment pr my eligibility for benefits from my health plan or other programs,	DIOCESS dilla Verilly III a state incurance marketolace (also known as an exchange)?
Name: Name:	support, and communicating with my healthcare providers, inclu	
Policy #: Group #: Re	prescription medication to me; 4) contacting me to evaluate the	
Check box if patient has secondary insurance coverage and fax a copy of ins	Gilead's internal business purposes, including quality control and	Indicate the second of the sec
5. PRESCRIBER INFORMATION (REQUIRED)	information, offers, and educational materials related to my treat	tment and/or my p reimbursement or credit for this medication from any insurer, health plan, or government program. If I am a member of a Medicare Part D plan, I will not seek
Prescriber Name: Fa	customer relationship marketing program (this use of my person the signatures below, I may opt in).	Indi IMIDITMIDION IS O reserves the right to modify the application form, modify or discontinue this program, or terminate assistance at any time and without notice. I authorize the PAPIMAP and its administrator to forward my prescription to a dispensing pharmacy on my behalf. I authorize Gilead and its third party administrator to use
Address: Cil	I understand that once my PHI has been disclosed hereunder, fed	the information provided on this form to obtain a personal credit report about me to verify the information on this form and determine my eligibility for
State: Zip Code: Of	I understand further that I may refuse to sign this authorization at	
Phone #: Fa	ability to obtain treatment from my healthcare providers will not	t change, but I will r REQUIRED ONLY IF APPLYING FOR PARIMAPI
Tax ID #: Sta	by Program and/or the PAP/MAP. I also understand that I may can	
	writing at Advancing Access, PO Box 13185, La Jolla, CA 92039-3	
DIAGNOSIS MEDICAL INFORMATION Diagnosis (Please include ICD code):	to obtain, use or disclose my PHI after the cancellation date, but the PHI that have already been made pursuant to this authorization between the pursuant to	
Diagnosis (Please Include ICD code).	signed authorization, which expires the earlier of two (2) years fro	
7. PRESCRIBER CERTIFICATION AND STATEMENT OF MEDICAL NECESSITY	under the laws of the state in which I reside.	
By signing this form, I certify that I am prescribing Gliead medication for the patient dentified in patient and that it will be used as directed. I certify that I will be suspensing the patient's treatms of my knowledge. I agree that I shall not seek reimbursement for any Gliead medication dispers Program (PAB/MAP) from any government program or this-fparty insurance.	By checking this box, I agree to receive marketing information, offers and ed	
If prescribing TRUVADA for PYEP", I certify that the applicant has been tested for HIV infection a	prescription medication, including the customer relationship marketing progr	gram.
applicant's care plan. As part of my applicant's eligibility, I agree to periodically verify continued. I certify that I have received the appropriate written authorization from the patient, in accordance of	SIGNATURE of PATIENT or PATIENT'S REPRESENTATIVE (REQUIRED):	
health information privacy law(s), and any other applicable requirements, in order to release the pa the purposes of: I) verifying the patient's insurance coverage and eligibility for benefits; 2) seeking		
support, and referral support as needed; 4) facilitating the provision of the patient's prescription in patient's prescription medication or to evaluate the effectiveness of the Advancing Access Progra		
PRESCRIBER SIGNATURE (REQUIRED):	Patient Representative's Name (if signing for the patient):	
© 2017 Glead Sciences, Inc. All rights reserved. ADMC0300 12/17	Patient Representative's Relationship to Patient:	
	FAX COMPLETED FORM TO ADVANCE	ICING ACCESS AT
	© 2017 Glead Sciences, Inc. All rights reserved. ADMC0300 12/17	
		ADVANCING ACCESS, GLEAD, the GLEAD logo, TRUVADA and TRUVADA for PrEP are trademarks of Glead Sciences, Inc., or its related companies.
		© 2017 Glead Sciences, Inc. All rights reserved. ADMC0300 12/17

State Plans

- Illinois IDPH PrEP Assistance Program
 - PrEP Navigation, funding for cost assistance through IDPH
- Massachusetts Massachusetts Pre-Exposure Prophylaxis Drug Assistance Program (PrEP-DAP)
 - Assistance for copays, co-insurance, full cost of Truvada ®
 - Limited to <500% FPL
- Washington Pre-Exposure Prophylaxis Drug Assistance Program (PrEP-DAP)
 - PrEP Navigation, assistance for medication and cost of labs/visits
 - No income limitation
- New York Pre-exposure Prophylaxis Assistance Program (PrEP-AP)
 - Assistance for cost of labs and provider visits
 - Enrollment criteria based on AIDS Drug Assistance Program (ADAP)
- California PrEP Assistance Program (PrEP-AP)
 - Launched early 2018
 - Assistance for cost of labs and provider visits
 - Limited to <500% FPL

Advice to patients

- Find out your deductible
- Find out your Truvada® copay
- Find out your estimated costs of visits and labs
- If you need an insurance plan from the marketplace, avoid Bronze Plans due to high out-of-pocket expenses
- Use Flexible Spending Account to offset any out-of-pocket expenses

Vanderbilt PrEP Clinic

- Sample: N=69
- Insurance plans: Cigna, Aetna, TennCare
- Specialty Pharmacies: Navitus, CVS Caremark, OptumRx, Express Scripts
- Copay range: \$30 \$400/month

Vanderbilt PrEP Clinic

- Patients paying any out-of-pocket cost: 11
 - TennCare (\$3 copay): 3
 - Qualified for assistance through foundation: 3
- Annual out-of-pocket costs (N=5): \$220 \$2400
 - Copay assistance goes toward deductible/out-of-pocket max until exhausted
 - Remainder of deductible paid throughout the remainder of the year

Other cost considerations

Encounter	To do
Month 0	 Screen for HIV Confirm HBV and HCV status Check serum creatinine Screen for STIs
Month 3	Screen for HIVCheck serum creatinine
Month 6	Screen for HIVScreen for STIs
Month 9	Screen for HIVCheck serum creatinine
Month 12	Screen for HIVScreen for STIs

Labs:

- HIV screen: 5

- Serum creatinine: 3

- STI screen: 3

- HBV screen: 1

- HCV screen: 1

Clinic visits: 5


Other:
HBV vaccination
STI Treatment

Cost effectiveness of PrEP Number needed to treat

- Number needed to treat
 - Inverse of absolute risk reduction
 - Varies depending on population
 - Key factors are HIV prevalence, acquisition risk factor, and efficacy of PrEP
 - In reality, these factors vary within a single population



Number needed to treat




Overall, NNT = 62 Lower NNT:

- Condomless anal receptive sex
- STIs
- Cocaine use

- Incremental cost effective ratio (ICER)
 - The difference in cost between two possible interventions, divided by the difference in their effect
 - Equivalent to the cost per quality-adjusted life year (QALY)
 - Cost effectiveness depends on the population
 - Very cost effective strategy = ICER < per capita GPD
 - Cost effective strategy = ICER < 3x per capita GDP





Cost effectiveness of PrEP in reducing HIV depends on:

- Extent of PrEP coverage
- Other factors that reduce HIV



- In San Francisco, expanding PrEP is cost-effective, especially when combined with early ART
 - PrEP for 80% of high-risk individuals would reduce new infections
 52% over 20 years
 - Cost of \$132,520 per QALY gained
 - Earlier ART would reduce new infections by 22% over 20 years
 - Cost of \$4745 per QALY gained
 - PrEP for 80% + earlier ART would reduce new infections by 57% over 20 years
 - Cost of \$115,320 per QALY gained

Per capita GDP of San Francisco = \$81,347Per capita GDP in San Francisco x 3 = \$244,041

- Cost per QALY gained varies by city and population
 - High-risk MSM in NYC: \$31,970
 - High-risk MSM in Los Angeles: \$27,863 \$37,181
 - High-risk MSM in USA: \$52,443
 - All MSM in USA: \$172,091 \$216,480

Per capita GDP of USA: \$57,466.79

- To make PrEP cost-effective:
 - Target those at highest HIV risk for intervention
 - Combine with other HIV-reduction efforts
 - Lower the cost of PrEP?

Patient scenarios

 29yoM presenting to discuss initiation of TDF/FTC for HIV risk reduction. He is MSM, has anal insertive and receptive sex with inconsistent condom use, and has a history of chlamydia. He is enrolled in an ACA Marketplace Bronze Plan. He is self-employed with an annual income for >\$70,000.

 He contacted his insurance company and discovered his monthly copay for Truvada is \$500.

Which assistance option will be most helpful in making Truvada® affordable?

- A. Patient Advocate Foundation (PAF)
- B. Gilead Advancing Access Program
- C. Gilead Medication Access Program
- D. Patient Access Network Foundation
- E. None, he can afford it

Which assistance option will be most helpful in making Truvada affordable?

- A. Patient Advocate Foundation (PAF)
- B. Gilead Advancing Access Program
- C. Gilead Medication Access Program
- D. Patient Access Network Foundation
- E. None, he can afford it

This is the Gilead copay assistance program

- No income limitations
- Up to \$7,200 benefit per calendar year
- Federal beneficiaries excluded

- Annual copay cost = $$500 \times 12 = 6000
- Copay cost is less than Gilead Advancing Access \$7200 annual benefit
- Out-of-pocket medication cost = \$0

65yoM who has been taking TDF/FTC for the past year.
He is married to a woman who is HIV+, engaged in care
and reportedly undetectable. He recently enrolled in
Medicare, but did not enroll in Part D. He therefore has no
coverage. He makes \$30,000 annually.

What can be done?

- A. Explore enrollment in Medicare Part D
- B. Gilead Medication Access Program
- C. Explore private foundations (PAN, PAF)
- D. All of the above

What can be done?

- A. Explore enrollment in Medicare Part D
- B. Gilead Medication Access Program
- C. Explore private foundations (PAN, PAF)
- D. All of the above

- Why didn't he enroll in Medicare Part D?
- If enrolled in Part D, PAN/PAF could offer copay assistance (but PAN not currently accepting applications)
- His most reliable immediate option is Gilead MAP

 41yoM is taking TDF/FTC and pays \$0 for medication thanks to the Advancing Access Program. He states he recently received a bill for \$800 following administration of ceftriaxone for gonorrhea diagnosed at his last visit. He now declines any STI testing. He reports 11 partners over the past 3 months with inconsistent condom use.

What would you recommend?

- A. Respect patient's autonomy and stop STI testing
- B. Test for STIs only every 6 months
- C. Discharge patient from your clinic as you cannot provide complete PrEP services
- Recommend STI testing at Health Department or FQHC

What would you recommend?

- A. Respect patient's autonomy and stop STI testing
- B. Test for STIs only every 6 months
- C. Discharge patient from your clinic as you cannot provide complete PrEP services
- Recommend STI testing at Health Department or FQHC
- Always advise patient to check with their insurance before ordering tests, scheduling visits, or administering medications.
- If high costs are anticipated, there may be alternative sites that offer these services at lower costs.

 You work at a large academic medical center. One of the partners of one of your HIV+ patients is interested in starting PrEP. He 34yoM, MSM, undocumented, uninsured and states cost is a major barrier for all of his healthcare. He recently received treatment for gonorrhea at an affordable local community health center.

What is his best option?

- A. Schedule him in your clinic and enroll him in the Gilead Medication Access Program
- B. Recommend he discuss PrEP with his prior provider
- Discuss enrolling him in Ryan White
- D. Combine multiple different cost assistance programs

What is his best option?

- A. Schedule him in your clinic and enroll him in the Gilead Medication Access Program
- B. Recommend he discuss PrEP with his recent provider
- Discuss enrolling him in Ryan White
- D. Combine multiple different cost assistance programs
 - This patient represents a significant high-risk group with low PrEP accessibility
 - Ryan White does not fund care for HIV-negative patients
 - He will need not only medication assistance, but assistance for labs and visits
 - FQHCs may have affordably discounted labs and visits. This, in combination with Gilead MAP, may make PrEP affordable
 - Could also investigate state funding, if available

Thank you!

Questions?